Blog
RSS FeedPosted by Michael Wonder on 23 Oct 2018
NZ patients with ALK positive non-small-cell lung cancer score a minor win
23 October 2018 - PTAC has recommended that alectinib hydrochloride be funded for the first-line treatment of ALK positive, locally ...
Posted by Michael Wonder on 22 Oct 2018
Hatred of big pharma won’t get us better drug prices
22 October 2018 - The story of how Remicade became Canada’s most lucrative drug with sales topping $1.1-billion – told ...
Posted by Michael Wonder on 22 Oct 2018
How pharma companies try to use funding to sway patient advocate groups
21 October 2018 - Like many patient advocacy groups, the Canadian Spondylitis Association – which is focused on arthritis in the ...
Posted by Michael Wonder on 22 Oct 2018
Lung cancer survivor wants PHARMAC to fund drugs she received in trial
22 October 2018 - Lung cancer patient Marjolein Baas takes the drug ceritinib, one of six lung cancer treatment drugs the ...
Posted by Michael Wonder on 22 Oct 2018
Pharmaceutical pricing conundrum: time to get rid of it?
21 October 2018 - A basic concept of economics is that a price stems from the intersection between supply and demand ...
Posted by Michael Wonder on 20 Oct 2018
Is the EUnetHTA HTA core model fit for purpose? Evaluation from an industry perspective
18 October 2018 - The HTA Core Model was developed to improve the transferability of health technology assessment between settings. ...
Posted by Michael Wonder on 20 Oct 2018
Cost, context, and decisions in health economics and health technology assessment
18 October 2018 - This study is an attempt to demystify and clarify the idea of cost in health economics ...
Posted by Michael Wonder on 20 Oct 2018
Some European countries decide to cover cancer drugs much faster than others
19 October 2018 - Some European countries take more than twice as long as others to decide whether to provide ...
Posted by Michael Wonder on 19 Oct 2018
Competition watchdog’s appeal over Pfizer ruling dismissed
19 October 2018 - The High Court has dismissed the ACCC’s application to appeal a decision on whether Pfizer’s local ...
Posted by Michael Wonder on 19 Oct 2018
NICE rejects Lilly’s breast cancer drug Verzenios
19 October 2018 - As it stands Eli Lilly’s Verzenios will not be routinely funded on the NHS for breast ...
Posted by Michael Wonder on 18 Oct 2018
Northland mum Alethea Nathan with lung cancer pleads for publicly-funded medicine
19 October 2018 - Alethea Nathan has lung cancer, she is relying on her Life Insurance payout to cover the high ...
Posted by Michael Wonder on 18 Oct 2018
NHS green light for Novartis skin cancer combo
18 October 2018 - The NHS now has three months to ensure that Novartis’ combination therapy dabrafenib/trametinib is routinely available ...
Posted by Michael Wonder on 17 Oct 2018
Lojuxta to be reimbursed in France
17 October 2018 - Amryt's lead commercial product now available in all five of the EU's largest markets ...
Posted by Michael Wonder on 17 Oct 2018
Further hepatitis C drug delay 'cruel'
18 October 2018 - PHARMAC's decision to extend consultation on introducing new hepatitis C drugs is cruel and devastating for ...
Posted by Michael Wonder on 16 Oct 2018
Cystic fibrosis patients worry about future of 'life-changing' drug
16 October 2018 - A drug review body has recommended the drug not be covered by public benefit programs. ...